Augmentation of tissue blood flow by therapeutic ultrasound is thought to rely on convective shear. Microbubble contrast agents that undergo ultrasound-mediated cavitation markedly amplify these effects. We hypothesized that purinergic signaling is responsible for shear-dependent increases in muscle perfusion during therapeutic cavitation.
D
istribution of blood flow in the body is tightly regulated to meet tissue metabolic and functional demand. Vascular conductance is determined primarily by microvascular tone, which is in part under the regulatory control of vasoactive substances that change according to metabolic substrate needs, pH, temperature, pressure, and shear. [1] [2] [3] Mechanistic knowledge of vasomotor control has been critical for developing therapies for hypertension, shock, tissue ischemia, and heart failure, most of which rely on pharmacological mimicry or modification of endogenous vasoactive substances. Shear-dependent vasodilation is a response mediated by endothelial-derived substances and is permissive for lowering vascular resistance in response to downstream hyperemia and reducing cardiac work during exercise based on how the radii of a branching tube system influences the energy of flow delivery. 2, 4 Ultrasound is increasingly used for a wide variety of therapeutic applications, some of which rely on ultrasound-mediated effects on perfusion. Vasodilation in large vessels and the microcirculation occurs in response to ultrasound over a wide frequency range and is thought to be secondary to oscillatory pressures or vascular shear produced by convective motion. 5 , 6 The presence of gas bodies within the microcirculation in the form of encapsulated microbubble contrast agents that undergo acoustic cavitation can produce high focal shear and markedly augment the effects of ultrasound on blood flow. 7, 8 Contrast-enhanced ultrasound (CEU) with MBs is being investigated as a promising therapy for acute ischemic syndromes.
With regard to the mechanism for flow augmentation during ultrasound cavitation, a direct coupling between ultrasound-mediated shear and nitric oxide (NO) release has been proposed previously. 6, 9, 10 In this study, we sought to investigate other key molecular pathways, including ATP release, which is known to influence blood flow through a combination of mechanisms that include conversion to adenosine and calcium-dependent endothelial purinergic receptor signaling that secondarily activates endothelial NO synthase (eNOS) and release of prostaglandin-derived vasodilators. We also sought to investigate whether ultrasound cavitation can reverse tissue ischemia in a murine model of chronic hindlimb ischemia and increase skeletal muscle blood flow in patients with sickle cell disease (SCD), a disease where abnormalities in perfusion are attributable, in part, to impaired endothelial-dependent vasoactive pathways. 11 
METHODS

Animal Models
The study was approved by the Animal Care and Use Committee of the Oregon Health & Science University. Wildtype C57Bl/6 mice and P2Y2 -/-mice (P2ry2 tm1Bhk /J) on a 129P2 background were obtained from Jackson Laboratory. Mice were studied at 10 to 20 weeks of age. Mice were anesthetized for study procedures with inhaled isofluorane (1.0-1.5%) mixed with room air and kept euthermic with external heating sources. For CEU studies, a jugular vein was cannulated for intravenous access. The unilateral hindlimb ischemia model was produced by ligation of the distal common iliac artery and the origin of the epigastric artery through a midline abdominal incision using sterile technique, after which mice were recovered and buprinorphine HCL (0.2 mg/kg IM) was administered for analgesia. Mice were restudied 20 to 25 days after surgical ligation to allow for completion of endogenous angiogenic responses.
Pathway Inhibition in Mice
Vasoactive signaling pathways were inhibited in mice with the following protocols that have been previously validated. Inhibition of eNOS was performed with 75 μg/kg L-nitroarginine methyl ester (L-NAME, Santa Cruz Biotech) given IP 30 minutes before study. Blockade of adenosine A 2 -receptors was performed with 50 μg/g of 4-(2-[7-amino-2-(2-furyl) [1, 2, 4] • Ultrasound, together with microbubble (MB) contrast agents, can markedly augment limb perfusion by several fold through a mechanism that involves vascular shear during MB cavitation.
• This flow augmentation relies on local release of ATP, which mediates vasodilation through direct purinergic signaling to increase production of nitric oxide and prostanoids, and through ectonucleotidase conversion to adenosine.
• Augmentation of perfusion with ultrasound and MBs extends well beyond the region insonified and can reverse limb ischemia in mice for >24 hours and improve skeletal muscle perfusion in patients with sickle cell disease.
What Are the Clinical Implications?
• Ultrasound cavitation of MBs represents a promising approach for rapidly correcting tissue perfusion in acute ischemic syndromes or for treating chronic ischemic symptoms.
• Cavitation-related release of ATP may serve to explain ultrasound's role in other therapeutic applications, such as wound and bone healing, and ultrasound-facilitated drug or gene uptake.
• The shear-and endothelial-dependent pathways activated by MB cavitation indicate that this approach could potentially be used to assess endothelial vasodilator function.
apyrase (Sigma-Aldrich) given IP 1 hour before study, whereas inhibition of ectonucleotidases involved in ATP metabolism was performed by 1 μg/g of sodium polytungstate (VWR) given by IP injection 30 minutes before study. Inhibition of the K ATP receptor was performed by 15 mg/kg glibenclamide (Santa Cruz Biotechnology) given IV 30 minutes before study. For inhibiting intracellular signaling pathways, L-NAME (20 mg/kg) was administered by IV route 10 minutes before imaging, and indomethacin (2 mg/kg) was given by IP route 24 hours and again 1 hour before study.
Microbubble Preparation
See online-only Data Supplement.
Murine Therapeutic Ultrasound Protocols
The proximal adductor muscles of the left hindlimb were exposed to therapeutic ultrasound for 10 minutes. A phasedarray transducer was placed at a fixed distance (3 cm) from the midportion of the muscle using a transverse imaging plane, and ultrasound was performed over 10 minutes using harmonic power-Doppler imaging (Sonos 7500, Philips Ultrasound) at 1.3 MHz triggered at 5-second intervals. For these pulses, a pulse repetition frequency of 9.3 kHz and a mechanical index (MI) of 1.3 were used. Microbubbles (2×10   8   ) were suspended in ≤200 μL of normal saline and administered over the first minute of ultrasound exposure.
Cavitation Detection
Murine Microvascular Perfusion Imaging
Contrast-enhanced ultrasound perfusion imaging of the proximal hindlimb adductor muscles of the therapeutic ultrasoundexposed and contralateral control limb was performed 10 minutes after therapeutic ultrasound. The nonlinear fundamental signal component from microbubbles (MBs) was detected using multipulse phase-inversion and amplitude-modulation (Sequoia 512, Siemens Medical Systems) at 7 MHz and an MI of 0.18 with a linear-array transducer. This form of lowpower imaging has been shown not to produce any detectable changes in perfusion. 8 Microbubbles were infused at a rate of 1×10 7 minute -1
. Time-intensity data at a frame rate of 5 Hz were acquired after a high-power (MI 0.98) 5-frame sequence and were fit to the function y=A(1-e βt ), where y is intensity at time t, A is the plateau intensity representing relative microvascular blood volume, and rate constant β is the microvascular flux rate. 12 Microvascular blood flow was quantified by the product of A and β.
12
Spatial Assessment of Flow Augmentation
The spatial extent of ultrasound cavitation-mediated increases in perfusion beyond the boundaries of the therapeutic ultrasound transducer was assessed. After completing therapeutic ultrasound cavitation in the short-axis plane of the hindlimb in mice, the location of the beam was marked and the diagnostic linear-array transducer was aligned in the long-axis (90° rotation from the therapeutic probe orientation). Microbubbles were infused at a rate of 1×10 7 minute -1 , and maximum intensity projection imaging using settings described above for perfusion imaging was performed for a 6-second acquisition after a high-power destructive pulse sequence at an MI of 0.98. Intensity was measured from within the therapeutic sector plane and at incremental distances (2, 4, and 6 mm) beyond the sector plane at 1, 3, and 6 seconds of maximum intensity projection imaging acquisition. Because flow augmentation was manifest primarily as an increase in β, the primary outcome measure on maximum intensity projection imaging was the regional intensity at the shortest (1-s) acquisition duration.
Ex Vivo Arterial Dilation
In Vivo Imaging of ATP Release 
Endothelial Cell and Erythrocyte ATP Release
Murine endothelial cells (SVEC4-10, ATCC) were grown to confluence in DMEM supplemented with 10% fetal bovine serum in 75-mm culture flasks. Immediately before study, DMEM was exchanged to capacity with fresh medium at 37°C containing 0.5 mg D-luciferin, 5 μg firefly luciferase, and 5×10 8 MBs. Optical imaging was performed after exposure to ultrasound for 1 minute at frame rate of 1 Hz otherwise using the same settings as the murine experiments. Human red blood cells (RBCs) from normal volunteers were obtained and washed, and 1 mL was diluted 1:34 with DMEM containing 0.5 mg D-luciferin, 5 μg firefly luciferase, and 5×10 8 MBs before US exposure. Combination experiments were performed with both RBCs and SVEC4-10 endothelial cells, and control experiments were performed without ultrasound but with a matched 1-minute delay in imaging. For each condition, results from 6 experiments were averaged. To evaluate for persistent ATP release (ie, mechanotransduction) after resolution of microporation (see below), experiments with endothelial cells were repeated with a 20-minute delay in adding D-luciferin and luciferase. For these experiments, DMEM exchange was performed 15, 10, and 1 minute before adding luciferin and luciferase. Control experiments with DMEM exchange were also performed.
Assessment of Cellular Poration
RBC Deformability
Muscle eNOS Phosphorylation
Phosphorylation of eNOS at Ser1177 was evaluated in muscle samples obtained from within the ultrasound imaging sector and from nonexposed muscle. Samples were obtained within 15 minutes of completion of ultrasound exposure. For enzyme-linked immunosorbent assay, bilateral hindlimb muscle samples were obtained from 9 wild-type mice, 5 P 2 Y 2 -/-mice, and 6 P 2 Y 2 -/-mice treated with ZM-241385. Samples were homogenized in lysis buffer containing 1 mM phenylmethylsulfonyl fluoride and then centrifuged, and the supernatant was evaluated for phosphorylated eNOS using a PathScan enzyme-linked immunosorbent assay (Cell Signaling Tech).
Assessment of Flow Augmentation in Patients With SCD
The study was approved by the Institutional Review Board of the Medical College of Wisconsin. Twelve black subjects with SCD (18±4 years of age; 4 males and 8 females) were studied. All subjects had a history of SCD (S/S HbB phenotype). Exclusion criteria included vaso-occlusive crisis within the previous 3 months, heart failure, significant right-to-left shunt, and allergy to ultrasound contrast agent. Therapeutic ultrasound cavitation and microvascular perfusion imaging were performed simultaneously using a protocol where MB replenishment kinetics are evaluated from the progressive prolongation of high-power destructive pulse sequences. 12 The proximal forearm flexor muscles (flexor digitorum superficialis and profundus) were imaged in the transverse plane ≈1/3 the distance to the wrist using a phased-array transducer interfaced with an ultrasound system (iE33, Philips Ultrasound). Power modulation imaging was performed using a broad-band pulse centered at 2.0 MHz at a mechanical index of 1.0, with the acoustic focus placed at the midmuscle level. One vial of lipidshelled octafluoropropane MBs (Definity, Lantheus Medical Imaging) was diluted to a total volume of 30 mL in 0.9% saline for a final concentration of 5×10 8 mL -1 . The MB suspension was infused IV at 1.5 mL/min. Imaging was started after allowing MB concentration to come to steady state (≈2 min). A short (2-to 3-s) continuous imaging sequence was followed by acquisition of intermittent frames obtained at incrementally increasing time intervals from every 1 to 15 cardiac cycles at end diastole by gating acquisition to the electrocardiographic R-wave. Several frames were acquired for each pulsing interval. The total time of acquisition was ≈3 to 4 minutes. This process was repeated 3 times over ≤15 minutes. Progressive prolongation of the pulsing interval guaranteed exposure of MBs to ultrasound within the entire span of the muscle circulation and also allowed quantification of perfusion. For the latter, several continuous imaging frames were averaged and digitally subtracted from averaged frames at each pulsing interval. Time versus background-subtracted video intensity data from the muscle were fit to the function y=A(1-e βt ), where y is intensity at time t, A is the plateau intensity representing relative microvascular blood volume, and the rate constant β is the microvascular flux rate. 12 Microvascular blood flow was quantified by the product of A and β. 12 The effect of MB cavitation was evaluated by comparing data from the first ultrasound prolongation sequence (0-5 min) to the third sequence (10-15 min).
Statistical Analysis
Data were analyzed using Prism (version 5.0, GraphPad Software). Groupwise differences were assessed by MannWhitney U test for data that were determined to be non-normally distributed by D'Agostino and Pearson omnibus test. For data with normal distribution, groupwise differences were assessed by 1-way analysis of variance with post hoc unpaired Student's t test and Bonferroni's correction when evaluating different testing conditions and paired Student's t test when comparing limbs exposed to ultrasound to control contralateral limbs. Differences were considered significant at P<0.05 (2-sided).
RESULTS
US Results in Immediate and Sustained Extracellular ATP Release
We first quantified the increase in limb muscle blood flow created by ultrasound-mediated cavitation in anesthetized adult C57Bl/6 mice undergoing ultrasound (1.3 MHz, mechanical index 1.3) delivered at a 5-second pulsing interval with a phased-array transducer placed over the left proximal hindlimb adductor muscle group. US was performed for 10 minutes after a single IV injection of lipid-shelled decafluorobutane-core MBs with a composition, zeta potential, and size distribution similar to that for certain commercially produced MB agents (see online-only Data Supplement Figure I ). These ultrasound powers, which are within the diagnostic range, do not produce significant adverse bioeffects but did generate inertial cavitation energy in vivo detected by broad-band signal, which indicates high-shear ultrasound events in the vascular compartment (Figure 1a) . After high-power ultrasound exposure, CEU perfusion imaging performed at very low power, which has no effects on tissue blood flow, 8 revealed a 6-fold increase in perfusion in the muscle exposed to US (Figure 1b to f) . This increase in perfusion was attributable mainly to an increase in the microvascular blood flux rate (β), with little increase in microvascular blood volume, which is an index of the number of microvascular units perfused. Reorientation of the probe to assess perfusion in the limb long axis was performed together with maximum-intensity projection imaging to evaluate the spatial distribution of flow after high-power therapeutic US, 13 which demonstrated flow augmentation throughout the entire proximal hindlimb (online-only Data Supplement Figure II) . However, the hyperemic response was greatest in the region exposed to high-power therapeutic US (Figure 1g and h and online-only Data Supplement Figure III) .
Microstreaming during ultrasound-induced cavitation of MBs produces focal shear stress that can be orders of magnitude greater than that produced by physiological flow.
14 Because extracellular ATP derived from both endothelial cells and RBCs is recognized as an important A, Passive cavitation detection obtained from the mouse hindlimb during ultrasound (1.3 MHz) exposure of IV infused MBs. Inertial cavitation is indicated by the broad-band signal between the harmonic peaks seen at a mechanical index of 1.3 but not at 0.2. B, Examples of frames obtained during low-power contrast-enhanced US (CEU) perfusion imaging from the proximal hindlimb adductor muscles, and (C) corresponding time-intensity data obtained from a control (non-ultrasound-exposed) and an ultrasound-exposed limb illustrating greater blood flow in the latter.. Data were obtained 10 minutes after exposure to high-power US for 10 minutes during IV microbubble (MB) infusion. BG indicates background. D, Microvascular blood flow, (E) microvascular flux rate, and (F) microvascular blood volume (MBV) (mean±SEM) in the contralateral control (Con) and ultrasound-exposed (US+MB) hindlimbs of mice obtained 10 minutes after therapeutic US. *P<0.01. G and H, Examples of CEU of the proximal hindlimb with maximal intensity projection in the long axis and mean (±SEM) intensity from the control and ultrasound-exposed (US+MB) limbs. Imaging was performed with a 90-degree rotation from therapeutic US plane 10 minutes after therapeutic US and illustrates distribution of perfusion within the 2-mm-wide therapeutic US sector plane (SP) and distal adjacent sectors at 2-, 4-, and 6-mm increments. *P<0.01 versus control limb. †P=0.05 versus control. I, In vivo optical imaging of intravascular ATP release by luciferin-luciferase activity in control and ultrasound-exposed (US+MB) limbs. Data were obtained at various intervals after completing a 10-minute US exposure during MB infusion. *P<0.001 versus control; †P<0.05 versus control. J, Examples of optical imaging illustrating focal ATP production at the site of US cavitation (left proximal hindlimb).
biological mediator of shear-dependent vasodilation, [15] [16] [17] [18] we investigated the temporal release of ATP within the vascular compartment after ultrasound cavitation. In vivo optical imaging was performed in anesthetized mice receiving IP d-luciferin 10 minutes before US and IV firefly luciferase 1 minute before completing US exposure. Photon flux from the ATP-dependent luminescent reaction was 40-fold higher in the ultrasound-exposed versus contralateral control hindlimb early after exposure (Figure 1i and j) . Focal ATP signal in the ultrasound-exposed limb decreased gradually over time and, although greatly attenuated by 24 hours, was still 5-fold greater (P=0.03) than in the contralateral nonexposed limb.
Flow Augmentation With US Cavitation Is Mediated by ATP
Because ultrasound cavitation produced immediate and sustained increases in ATP release, we examined whether ultrasound-mediated augmentation of perfusion was affected by modifying vasoactive pathways mediated by ATP. Membrane-bound and soluble ectonucleosidases, including nucleoside triphosphate diphosphohydrolases (NTPDase) of the CD39 family, degrade ATP and ADP to AMP, whereas ecto-5'-nucleotidase (CD73) degrades AMP to adenosine. [18] [19] [20] These enzymes also have been shown to be released in response to shear. 18 Adenosine produces vasodilation mostly through Gs-coupled A 2A or A 2B on smooth muscle cells or on endothelial cells where vasodilation is mediated in part by phosphorylation and activation of eNOS. [21] [22] [23] As a first step to investigate the roles of adenosine and ATP, mice undergoing ultrasoundmediated cavitation of the hindlimb were pretreated with the A 2 receptor antagonist ZM241385 or the ectonucleotidase (CD39) inhibitor sodium polyoxotungstate. 24 Adenosine receptor blockade alone had no significant effect on muscle perfusion, whereas sodium polyoxotungstate modestly reduced both microvascular flux rate and blood flow (Figure 2a and online-only Data Supplement Figure IV) . Direct ATP signaling through endothelial G-coupled P 2 Y purinergic receptors has been shown to produce vasodilation in skeletal muscle and mesenteric microcirculation, albeit with less of an effect in the coronary circulation.
16,25-27 Accordingly, we investigated the role of direct ATP signaling in ultrasound-mediated augmentation of perfusion. Administration of apyrase as an exogenous CD39-like nucleotidase that rapidly degrades ATP did not change blood flow response to ultrasound cavitation (Figure 2a and online-only Data Supplement Figure IV) . We then tested the possibility that both the P 2 Y and adenosine pathways could be mutually compensatory with regard to their vasodilatory effects (ie, ability to shuttle between the pathways) by 2 separate approaches. First, wild-type mice were pretreated with both apyrase to promote ATP degradation and ZM241385 to inhibit adenosine A 2A and A 2B receptors, the latter of which has been shown alone to not influence flow augmentation. 8 Second, mice deficient for the major P 2 Y endothelial receptor in skeletal muscle microvasculature (P2Y 2 -/-) were studied after treatment with ZM241385. These 2 approaches resulted in a similar and substantial reduction in perfusion in the ultrasound-treated limb (Figure 2a and online-only Data Supplement Figure IV) , indicating that vasodilation in response to ultrasound-mediated cavitation is largely mediated by a combination of purinergic pathways. Because activation of endothelial or smooth muscle K ATP channels by ATP efflux represents an alternative pathway by which adenosine can mediate vasodilation, 21 we investigated the effect of receptor blockade with glibenclamide, which was found not to have a major effect on US cavitation-mediated augmentation in flow (Figure 2b and online-only Data Supplement Figure IV) .
Because our data indicated that augmentation in perfusion from US cavitation is mediated, in part, through the endothelial P2Y 2 receptor, we investigated the signaling pathways that are thought to mediate the vasoactive effects of P 2 Y receptor activation, including calcium-dependent phosphorylation of eNOS and phospholipase-A 2 -mediated production of vasoactive arachidonic acid metabolites. 16, [28] [29] [30] Skeletal muscle from wild-type mice exposed to ultrasound-induced MB cavitation demonstrated significant increases in phosphorylated eNOS by enzyme-linked immunosorbent assay (Figure 2c ). Because eNOS phosphorylation can occur by alternative non-P2Y-receptor-mediated processes, including K ATP and A 2B receptor activation, H 2 O 2 , and other endothelialderived hyperpolarizing factors, 21 ,22,31 we also evaluated phospho-eNOS in P2Y 2 -/-mice with and without inhibition of adenosine receptors. In these animals, cavitationmediated phosphorylation of eNOS was lower than in wild-type mice (Figure 2c ). To investigate the functional significance of inhibiting both the eNOS and arachidonic acid pathways downstream from P 2 Y activation, wild-type mice were pretreated with the eNOS inhibitor L-N G -nitroarginine methyl ester or indomethacin. Each of these interventions decreased flow augmentation produced by US cavitation, whereas the combination of the 2 essentially abolished flow augmentation (Figure 2d and online-only Data Supplement Figure IV) .
In aggregate, our data indicate the ATP is a critical mediator of flow augmentation produced by ultrasound cavitation and can act through either P2Y receptor signaling or adenosine produced by ectonucleotidase activity.
Cell Source for Cavitation-Mediated ATP Release
Whereas US alone influences pressure and shear conditions of all cell types within the acoustic field, the augmentation of shear-mediated effects with MB cavitation is limited to focal regions within the vascular space where MBs are confined. 32 Both endothelial cells and RBCs are in close proximity to MBs, and both release ATP in response to shear. 15, 17, 18, 33 We used an extracellular luciferin-luciferase assay to quantify ATP release from cultured microvascular endothelial cells (SVEC4-10 derived from SV40 transformation), human RBCs, or a combination of the 2. These studies demonstrated immediate release of ATP from both cell types after exposure to ultrasound-mediated MB cavitation (Figure 3a  and b) . The functional impact of RBCs was further investigated by assessing vascular response in a perfused ex vivo microvascular preparation. The diameter of rat mesenteric arteries increased incrementally with sequential ultrasound exposure of MBs without and with RBCs (40% volume) (online-only Data Supplement Figure V) .
Potential mechanisms for ATP release include mechanotransduction with the opening of shear-dependent ATP channels that have been identified on RBCs and endothelial cells such as pannexins 15, 34, 35 or transient (<10 min) microporation that can occur with MB cavitation. 36 The extent and duration of endothelial cell microporation was assessed by nuclear DNA fluorescence from propidium iodide (PI), which is normally excluded by intact cell membranes. PI was added to the culture medium of untreated cells or to cells at the time of ultrasound exposure or 10 or 20 minutes after exposure. Nuclear PI fluorescence was seen in the vast majority of cells when PI was ambient at the time of ultrasound cavitation but only in ≈15% to 20% of cells when PI was added at 10 or 20 minutes after ultrasound (Figure 3c and d) . These data indicate cavitation-mediated microporation of most cultured cells as a potential contributor to ATP release with permanent loss of viability (indicated by late PI staining) in only a small percentage. To investigate for sustained ATP release by mechanotransduction after resolution of microporation, optical imaging after ultrasound cavitation -/-mice treated with the adenosine A 2a receptor antagonist ZM241385 (ZM). *P<0.05 versus control; †P<0.05 versus no inhibitor. B, Mean (±SEM) microvascular flux rate in contralateral control and ultrasound-exposed limbs in wild-type mice with and without pretreatment with glibenclamide. *P<0.05 versus untreated control limb; P=ns between control and glibenclamide groups. C, Skeletal muscle phosphorylated endothelial nitric oxide synthase (eNOS) by enzyme-linked immunosorbent assay (ELISA) from control and US cavitation-exposed legs in wild-type (WT) (n=9), P2Y 2 -/-(n=5), and P2Y 2 -/-ZM-treated (n=6) mice. *P<0.05 versus control limb; †P<0.05 versus corresponding wild-type US+MB conditions. D, Mean (±SEM) microvascular flux rate in control and ultrasound-exposed limbs in wild-type mice pretreated with L-N G -nitroarginine methyl ester (L-NAME), indomethacin, or L-NAME and indomethacin. *P<0.05 versus control; †P<0.0001 versus no inhibitor. E, Examples of time-intensity curves and (F) contrast-enhanced US (CEU) perfusion images from variable times (t sec ) after the destructive frame from a control limb, and limbs exposed to US+MB with and without L-NAME+indomethacin treatment.
was repeated with a 20-minute delay in adding luciferinluciferase to endothelial cells with several interval lowshear medium exchanges. Persistent ATP release was detected after allowing time for resolution microporation (Figure 3e) , which is consistent with mechanotransduction as a second mechanism and serves to explain the sustained local in vivo ATP release detected as late as 24 hours after ultrasound (Figure 1i and j) . We confirmed that RBCs also undergo transient microporation similar to that seen for endothelial cells by using flow cytometry, which detected positive fluorescent staining of RBCs after exposure to ultrasound cavitation in the presence of Texas red-labeled dextran (Figure 3f (-US+MB) and ultrasound-exposed (+ US+MB) conditions. *P<0.01 versus corresponding control conditions (-US+MB); †P<0.05 versus EC; ‡P<0.01 versus EC and RBC. C, Fluorescent microscopy illustrating di-I-stained ECs (green) with positive nuclear propidium iodide (PI) staining (red), which was much more extensive when PI was ambient at the time of MB cavitation (left) than when PI was added after a 20-minute delay (right). Scale bar = 25 μm. D, Number of cells per optical field (OF) with positive nuclear staining when PI was ambient at the time of MB cavitation or was added after 10-or 20-minute delay. *P<0.0001 versus control; †P<0.001 versus ambient. E, ATP activity from endothelial cells with and without a 20-minute delay in adding luciferin and luciferase with interval medium exchange. Control conditions with medium exchange alone are also shown. F, Flow cytometry of RBCs exposed to FITC dextran without cavitation (-US+MB) or with cavitation (+ US+MB). The center histogram illustrates the presence of fluorescent RBCs from microporation, which was not seen when FITC dextran was added 20 minutes after US (bottom). G, RBC deformability expressed as the elongation index at various shears for RBCs exposed to US and MBs and for control RBCs. increasing time between ultrasound cavitation and addition of labeled dextran. To ensure that ATP release from RBCs did not influence their deformability, which has a major influence on relative effective viscosity and resistance at the capillary level, 37 laser-assisted RBC deformability measurements were made and confirmed no effect from cavitation (Figure 3g ).
Ultrasound Cavitation as Therapy
The ability to almost immediately increase skeletal muscle perfusion with ultrasound cavitation represents a potential therapy for rapidly reversing limb ischemia in subjects with limb ischemia due to severe peripheral artery disease. To examine the effect of US cavitation on ischemic limb perfusion, a murine model of chronic peripheral artery disease was produced by ligation of several major limb inflow vessels to produce moderate ischemia. 38 Because hypoxia is a recognized stimulus for ATP release from RBCs, 39, 40 we first performed in vivo optical imaging to examine whether ultrasound cavitation stimulates ATP release in the setting of chronic ischemia. Focal ATP release was seen at the site of ultrasound exposure (Figure 4a and b) , albeit to a lesser extent than that seen in the nonischemic setting. We then examined the ability of ultrasound cavitation to reverse limb ischemia in the murine model. These studies demonstrated augmentation of perfusion in the ischemic hindlimb to a degree that was higher than in the control nonischemic contralateral limb early after ultrasound exposure and similar to that in the control nonischemic limb at 24 hours (Figure 4c and d) . Again, the beneficial vascular effect extended distally in the limb beyond the area exposed to therapeutic US (online-only Data Supplement Figure VI) .
To investigate the beneficial effects of ultrasound cavitation on perfusion in humans, we studied patients with SCD in whom an imbalance in vasoactive intermediates contributes to pathophysiology. 11 Data also suggest that hydroxyurea, a commonly used treatment for SCD, produces NO-mediated vasodilation, in part, through RBC release of ATP. 41 Accordingly, in 12 patients with SCD not in vaso-occlusive crisis, ultrasound (1.3 MHz) was applied to the proximal forearm at a mechanical index of 1.3 during IV administration of lipid-shelled octafluoropropane MBs. In these experiments, therapeutic and diagnostic perfusion imaging were simultaneously performed by progressive prolongation of the interval between ultrasound frames from every 1 to 15 cardiac cycles, which allowed for construction of time-intensity curves and high-power exposure of MBs to ultrasound at various levels of the microcirculation. Three separate acquisitions (3-minute exposure) were performed at ≈5-minute intervals. Muscle perfusion in the flexor digitorum superficialis and profundus increased on average by 2-fold between the first ultrasound exposure (at 0-5 minutes) and the final ultrasound exposure (10-15 minutes) (Figure 4e ). This cavitation-mediated increase in perfusion was attributable primarily to an increase in microvascular blood flux rate (β) (Figure 4f to 4h ).
DISCUSSION
Therapeutic ultrasound over a wide range of frequencies and pressures is currently used for treating a wide range of diseases. High-intensity and highly focused ultrasound is widely used in patients for tissue ablative therapy, such as for benign or malignant tumors or renal calculi. The nonthermal bioeffects responsible for ablative therapy include cavitation events that disrupt tissue through shear produced by microstreaming and shock wave. Nonthermal shear forces are also thought to participate in the beneficial effects of lower amplitude ultrasound on tissue healing and blood flow.
Gas bodies in the form of membrane-stabilized MB contrast agents, including those that have undergone regulatory approval for diagnostic applications, act as cavitation nuclei within the microcirculation and have been shown to amplify ultrasound-mediated augmentation of perfusion. 8, 42 For limb perfusion, preclinical studies have demonstrated that the addition of MBs to ultrasound alone results in a >5-fold greater effect on muscle blood flow and a greater increase in arterial dilation. 8 The effects of CEU on perfusion are greatest when the acoustic power is high enough to produce inertial cavitation (exaggerated MB oscillation and destruction) and there is also sufficient time between ultrasound exposures to allow refill of MBs into the ultrasound sector. 8 These findings indicate that focal intense shear events caused by cavitation events that occur infrequently (every 5 sec in this study) and sparsely within the microcirculation are more effective at increasing vascular conductance than exposure of the entire microcirculation devoid of MBs to continuous US energy. 8 Although speculative, a potential explanation for this finding is that vascular effects may occur remotely from the site of cavitation because both focal mechanical stress and ATP release result in the propagation of calcium waves to activate endothelial cell networks. 43, 44 The biophysical events produced by MB cavitation have been shown to initiate cellular responses known to be important in the regulation of vascular tone. Cavitation-mediated increases in endothelial NO production and intracellular calcium have been described and attributed to activation of vaguely defined endothelial shear mechanotransducers or to transient membrane microporation. 6, 8, 9, 45 In this study, we have defined a multifaceted pathway (schematically illustrated in Figure 5 ), by which cavitation increases microvascular perfusion and that is not simply from direct mechanotransductive activation of eNOS. Cavitation produces a large ATP release from both endothelial cells and RBCs. The temporal pattern of this release suggests that an immediate phase from microporation is followed by sustained release that likely reflects either previously described shear-sensitive opening of ATP channels such as pannexin 1 or ATP-mediated ATP release. 15, 34, 44 Based on our varied manipulations of potential vasoactive pathways, it appears that the mechanism for flow augmentation can be "shuttled" between either P2Y receptor activation or ecto-nucleotidase degradation of ATP to adenosine. There was no major contribution from K ATP receptor activation. Irrespective of which receptor pathway was stimulated, the downstream events involve both activation of eNOS and production of prostanoids such as prostacyclin presumably downstream from calcium-dependent PLA 2 activity. 16, 21, 30 The mechanistic insights from this study are important for several reasons. They are important for understanding how to optimize cavitation for therapeutic benefit beyond the preliminary observations that we have performed in mice with limb ischemia and patients with SCD. The ability to increase tissue perfusion in a highly targeted fashion could be important for improving symptoms in chronic ischemic coronary and peripheral artery disease, reversing acute ischemic emergencies (eg, stroke, acute coronary syndrome, threatened limb loss), improving tissue-specific functions that rely on adequate perfusion (eg, renal and pancreatic function, tissue healing), or even possibly treating Alzheimers. 46 From a diagnostic standpoint, provocative noninvasive tests for assessing shear-mediated flow augmentation could provide a robust approach for assessing endothelial health. Currently, noninvasive assessment of endothelial health commonly involves the measurement of small changes in large arterial diameter that are produced during postocclusive hyperemia.
The discovery of ATP as a mediator of cavitation-mediated augmentation in perfusion, together with observation of flow augmentation outside of the region of cavitation, serves as an applied example of how focal mechanical events can lead to a global microvascular network response. We presume that this response reflects calcium wave propagation, which can be mediated by ATP release. 44 Finally, downstream effects from ATP signaling are likely to contribute to other therapeutic uses of ultrasound, such as for drug or gene delivery and tissue healing, which are thought to rely on calcium-dependent uptake.
Several limitations of this study must be acknowledged. Dose response in terms of ultrasound energy, frequency, or duration was not performed with regard to ATP release. Instead, we used ultrasound parameters, which we have previously demonstrated to produce a marked increase in limb perfusion and which do not produce any unwanted adverse bioeffects such as microvascular hemorrhage. 8, 47 In these previous studies, flow augmentation was dose-dependent with regard to MB dose and ultrasound power. An important limitation is that we have not yet identified the channel or other mechanism responsible for the sustained phase of ATP release. The models nec- essary for evaluating ATP release mechanism are not yet available to us for study. It should also be acknowledged that the clinical trial in patients with SCD was performed as a proof-of-concept study without rigorous attention to optimization of power, MB dose, or field exposure.
In conclusion, in this study, we have demonstrated that increased vascular conductance from ultrasound cavitation is mediated by a diverse portfolio of calciumdependent ATP signaling pathways, including endothelial purinergic P2Y-receptor activation and extracellular conversion of ATP to adenosine. Both of these pathways acted through eNOS and production of vasoactive prostanoids. These vascular effects of ultrasound cavitation can reverse hindlimb ischemia in mice for >24 hours and increase skeletal muscle blood flow by ≈2-fold in patients with SCD.
